

Contact: Christina Roche, 781-431-0700; croche@jdrf.org

42nd Annual JDRF Greater New England Gala– One Night

BOSTON, MA, January 16, 2024—The JDRF Greater New England Chapter is pleased to announce the 42nd Annual Gala–*One Night* on Saturday, April 6, 2024, taking place at the Omni Boston Hotel at the Seaport. As one of the area's premier charity events, the JDRF Gala will welcome more than 800 guests with the goal to raise more than \$2.5M for critical type 1 diabetes (T1D) research.

Hosted by emcees Vanessa Welch and Mark Ockerbloom of Boston 25 News, this black-tie event will feature exciting one-of-a-kind silent and live auctions, cocktails and dining, live entertainment, and JDRF's signature *Fund A Cure* program—in which contributions are 100% tax-deductible and will drive cutting-edge research.

This year's Gala Honorees, Lisa and Neil Wallack, are longtime JDRF supporters who are being recognized for their steadfast commitment to JDRF's mission to accelerate life-changing breakthroughs to cure, prevent, and treat T1D and its complications. Lisa's initial involvement with JDRF began 50 years ago through her parents, Marilyn and Gerald Fishbone, who were among the founders of JDRF after her brother Scott was diagnosed with T1D. Lisa and Neil increased their engagement with the Greater New England Chapter after their son, Harris, was diagnosed with T1D in 2001. As a result of their ongoing passion and dedication, countless JDRF initiatives at the local, national, and international levels have benefitted from their impactful contributions. In search of cures and better treatments for T1D, they have been instrumental in connecting the scientific community with those living with T1D.

For more information on event details, sponsorship, donation, and ticket options, as well as volunteer opportunities, please visit <u>https://bit.ly/jdrfgala2024</u> or contact Christina Roche, Development Director, JDRF Greater New England Chapter at 781-431-0700, <u>croche@jdrf.org</u>.

About Type 1 Diabetes (T1D)

T1D is an autoimmune disease in which insulin-producing beta cells in the pancreas are mistakenly destroyed by the body's immune system. T1D seems to have a genetic component and can be diagnosed early in life but also in adulthood. People with T1D are dependent on injected or pumped insulin to survive. Its causes are not fully known, and there is currently no cure.

About JDRF

JDRF is the leading global nonprofit funding T1D research, advocating for policies that accelerate access to new therapies, and providing a support network for millions of people impacted by T1D. JDRF has driven nearly every major advance in drug, device, and cell therapy made in T1D in the last 50+ years, and has invested more than \$2.5 billion in research funding. We are an organization built on a grassroots model of people connecting in their local communities, collaborating regionally for efficiency and broader fundraising impact, and uniting on a national stage to pool resources, passion, and energy. We collaborate with academic institutions, policymakers, and corporate and industry partners to develop and deliver a pipeline of innovative therapies to people living with T1D.

For more information, please visit <u>www.jdrf.org</u> or follow us on social media: Facebook (<u>www.facebook.com/jdrfgreaternewengland</u>); Instagram (<u>www.instagram.com/jdrfgreaternewengland</u>); LinkedIn (<u>www.linkedin.com/company/jdrfnewenglandchapter/</u>); Twitter (<u>www.twitter.com/JDRFGNE</u>).